MastOR SAS is a medical device company based in Paris, France, founded in 2019. The company focuses on developing a surgical robot designed to assist with laparoscopy, a minimally invasive surgical technique. This innovative platform aims to enhance access to advanced surgical procedures for surgeons and improve resource utilization in operating rooms. By providing tools that facilitate laparoscopy, MastOR seeks to advance surgical practices and patient care.
Cara by HiDoc Technologies is a Berlin-based pharmaceutical company established in 2015 that focuses on empowering patients with chronic digestive diseases. The company develops digital therapeutics aimed at enhancing existing therapies for gastrointestinal disorders. Cara's primary offering is a virtual health advising application that allows users to maintain a personal food and symptom diary. This application enables patients to track their dietary choices and record symptoms such as pain and bloating, helping them identify patterns related to their health. By providing tools for self-monitoring and understanding their conditions, Cara seeks to facilitate better health management for individuals suffering from digestive issues.
MastOR SAS is a medical device company based in Paris, France, founded in 2019. The company focuses on developing a surgical robot designed to assist with laparoscopy, a minimally invasive surgical technique. This innovative platform aims to enhance access to advanced surgical procedures for surgeons and improve resource utilization in operating rooms. By providing tools that facilitate laparoscopy, MastOR seeks to advance surgical practices and patient care.
Locus Biosciences is a developer of a CRISPR-engineered precision antibacterial platform designed to revolutionize the treatment of bacterial disease. The company's platform combines the antibacterial power of CRISPR-Cas3 with the efficient, safe delivery of bacterial viruses called bacteriophage, enabling physicians to begin treatment more quickly, resulting in a better medical outcome.
Operator of a biotechnology platform intended to increase binding affinity and improve consistency to help create personalized, precision cancer vaccines for patients of all backgrounds. The company's platform focuses on developing a single-molecule, massively parallel, de novo next-generation protein sequencing platform, enabling scientists and researchers to develop novel therapeutics and diagnostics and ultimately understand human biology and disease.
Operator of a biotechnology company intended to provide services regarding the functional manipulation of immune cells. The company maps human tissue's behavior to disease processes, allowing it to identify and characterize novel targets for therapeutic intervention, enabling patients to get access to treatment and cure themselves of debilitating illnesses including cancer, fibrotic, autoimmune and inflammatory diseases.
On Target Laboratories, LLC engages in discovering, developing, and commercializing small molecules that target specific pathological cells, when conjugated with fluorescent dyes. It offers folate and other targeting agents that target, lung, uterine, kidney, breast, colon, pancreatic, and prostate cancer cells. The company was incorporated in 2010 and is based in Northbrook, Illinois.
Aro Biotherapeutics is focused on the development of a new protein drug platform called Centyrins, designed to achieve better efficacy and safety profiles for patients with cancer and other serious diseases. Centyrins are small, non-antibody protein scaffolds that can be expressed as multi-specifics with novel therapeutic mechanisms of action. Centyrins are also ideal for the targeted delivery of complex drug payloads, including nucleic acids.
Dermala Inc. is a biotech company based in San Diego, California, that specializes in developing treatments for chronic skin diseases through the human microbiome. The company offers an innovative range of personalized topical and oral products aimed at addressing conditions such as acne, eczema, and skin aging. Its flagship FOBO Kit contains prebiotics and microbiome metabolites that target acne-causing bacteria while fostering beneficial skin flora. Dermala's products are designed to decrease skin oiliness, unclog pores, and reduce inflammation, effectively combating both antibiotic-resistant strains of bacteria and promoting overall skin health. Additionally, Dermala has developed an application that utilizes data analytics, machine learning, and artificial intelligence to track treatment outcomes and optimize therapies. The company markets its products directly to consumers through its website and was incorporated in 2014.
XW Laboratories Inc. is a biopharmaceutical company based in Wuhan, China, specializing in the discovery and development of innovative treatments for neurological disorders. Established in 2014, the company has created three distinctive research and development platforms, including Prodrug and Functional Group Switch, which facilitate the rapid identification of new drug candidates while minimizing development costs and time. XW Laboratories aims to enhance patient compliance and reduce toxicity associated with existing medications. In addition to focusing on the domestic market, the company collaborates with international partners to extend its reach in foreign markets, positioning itself at the forefront of medicinal technology in the Asia-Pacific region.
2 out of 3 men will start to lose their hair by the age of 35 - but the earlier you take action, the more hair you keep. Keeps is a full-service healthcare company focused exclusively on helping men keep their hair. From expert diagnosis to affordable treatment, patient support to education, Keeps provides a regimen specific to each customer's condition through a seamless digital experience, allowing men to manage hair loss from start to finish. Keeps’ licensed physicians review each customer's information in order to identify and prescribe a unique treatment plan of FDA-approved products, and we sell them at half the price customers would pay at their local pharmacy. With Keeps, customers receive exactly what they need, and nothing they don’t. Keeps is the first brand from Thirty Madison, which is rebuilding the healthcare experience for the modern consumer.
Legend Biotech Corporation is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative cell therapies for oncology and other medical conditions. Its primary product candidate, LCAR-B38M/JNJ-4528, is an autologous CAR-T cell therapy aimed at treating multiple myeloma by targeting the B-cell maturation antigen. The company is actively conducting clinical trials to assess this therapy as an earlier treatment option and to compare its effectiveness against standard triplet therapy in patients resistant to Revlimid. Additionally, Legend Biotech has a diverse portfolio of earlier-stage autologous product candidates that address various cancers, including non-Hodgkin lymphoma, acute myeloid leukemia, and T cell lymphoma. The company is also developing an allogeneic CAR-T product candidate targeting CD20, currently in a Phase 1 clinical trial in China. Besides its focus on blood cancers, Legend Biotech is exploring therapies for solid tumors and infectious diseases. Founded in 2014 and based in Somerset, New Jersey, Legend Biotech operates as a subsidiary of Genscript Biotech Corporation.
Adicet Bio is a biotechnology company focused on the discovery and development of allogeneic gamma delta T cell therapies for cancer and other diseases. The company is advancing its lead product candidate, ADI-001, which is a first-in-class allogeneic gamma delta T cell therapy designed to target CD20. This therapy aims to address relapsed or refractory aggressive B cell non-Hodgkin's lymphoma and potentially autoimmune diseases. Additionally, Adicet Bio is developing another preclinical candidate, ADI-270, which is an armored gamma delta CAR T cell therapy targeting renal cell carcinoma, with prospects for treating other solid tumors and hematological malignancies that express CD70.
Carbon, Inc. specializes in digital manufacturing solutions, focusing on the design, development, and production of advanced 3D printing technologies. The company's proprietary Digital Light Synthesis (DLS) technology incorporates digital light projection, oxygen-permeable optics, and programmable liquid resins to create high-quality parts with superior mechanical properties and surface finishes. Carbon's offerings include the SpeedCell system for streamlined production, additive manufacturing machines based on Continuous Liquid Interface Production (CLIP) technology, and automated Smart Part Washers. These innovations support various industries, including automotive, consumer products, dental, industrial, and life sciences, by enabling mass customization and on-demand inventory, while reducing waste and production time. Additionally, Carbon provides a range of polyurethane materials and consulting services to enhance manufacturing capabilities. Founded in 2013 by Dr. Joseph DeSimone and Philip DeSimone, Carbon is headquartered in Redwood City, California.
Carbon, Inc. specializes in digital manufacturing solutions, focusing on the design, development, and production of advanced 3D printing technologies. The company's proprietary Digital Light Synthesis (DLS) technology incorporates digital light projection, oxygen-permeable optics, and programmable liquid resins to create high-quality parts with superior mechanical properties and surface finishes. Carbon's offerings include the SpeedCell system for streamlined production, additive manufacturing machines based on Continuous Liquid Interface Production (CLIP) technology, and automated Smart Part Washers. These innovations support various industries, including automotive, consumer products, dental, industrial, and life sciences, by enabling mass customization and on-demand inventory, while reducing waste and production time. Additionally, Carbon provides a range of polyurethane materials and consulting services to enhance manufacturing capabilities. Founded in 2013 by Dr. Joseph DeSimone and Philip DeSimone, Carbon is headquartered in Redwood City, California.
Artizan Biosciences develops small molecule drugs targeting human diseases, utilizing its IgA-SEQ technology platform to identify disease-driving bacteria within the intestinal microbiota. Founded in 2016 and headquartered in New Haven, Connecticut, the company focuses on creating new and potentially curative treatments. With a commitment to advancing pharmaceutical drug development, Artizan Biosciences aims to address unmet medical needs through innovative approaches in biotechnology.
TechsoMed is an Israeli based medical device company, developing ultrasound based real-time monitoring systems for thermal ablation procedures. The applications of thermal ablation are numerous: tumor destruction, heart arrhythmia, blood pressure treatments and more. The procedure has market size in the billions, but lacks real-time monitoring capabilities, causing high failure rates.
Their technology offers added value to patients, physicians and insurance companies by solving the high failure rate of these minimally invasive and cost effective procedures.
Twentyeight-Seven, Inc. is a biotechnology company based in Watertown, Massachusetts, specializing in the development of small molecules that modulate microRNAs (miRNAs) by targeting the proteins that interact with these molecules. Their innovative approach focuses on using short non-coding RNAs to inhibit gene expression, suppress mRNA translation, and promote mRNA decay. By targeting miRNAs that play a critical role in cancer initiation, progression, and metastasis, Twentyeight-Seven aims to create effective therapeutic solutions for cancer treatment.
HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels.
Inivata Limited is a clinical cancer genomics company based in Cambridge, United Kingdom, established in 2014. The company specializes in the analysis of circulating tumor DNA (ctDNA) to enhance cancer testing and treatment for oncologists and their patients. By utilizing its TAm-Seq technology, Inivata enables the detection and analysis of genomic material from a patient's cell-free ctDNA, collected through a simple blood sample. This non-invasive method, known as liquid biopsy, represents a significant advancement in cancer diagnostics, allowing for improved detection, monitoring, and treatment decision-making. Inivata has also formed a strategic collaboration with NeoGenomics, Inc. to further strengthen its capabilities in this field.
Hyalex Orthopaedics, Inc. is a medical device company based in Lexington, Massachusetts, focused on developing innovative products that utilize HYALEX technology, a synthetic polymer engineered to mimic cartilage. Founded in 2016, the company specializes in creating a biomimetic material that can effectively simulate healthy cartilage to treat diseased or damaged joints. The unique properties of HYALEX allow it to maintain low friction and wear, even under the significant loads typically experienced in human joints. This capability enables surgeons to replace arthritic cartilage while preserving healthy bone. Although Hyalex Orthopaedics is advancing its product development, its offerings have not yet received approval for use in humans from any regulatory agency.
Calypso Biotech SA is an immunotherapy biotechnology company based in Plan-les-Ouates, Switzerland, founded in 2013 as a spin-off from Merck Serono. The company specializes in discovering and developing monoclonal antibodies aimed at treating immune pathologies, particularly for conditions with significant unmet medical needs, including severe gastrointestinal diseases. Calypso Biotech operates as a semi-virtual organization, leveraging a highly experienced management team with expertise in drug development. The company focuses on creating substantial value for investors through a portfolio of unique proprietary antibody candidates designed to control homeostasis and improve treatment outcomes for patients.
BiomX Inc. is a clinical-stage company based in Ness Ziona, Israel, focused on developing bacteriophage-based therapies that target harmful bacteria linked to various diseases. The company aims to treat conditions associated with microbiome imbalances, including skin conditions, inflammatory bowel diseases, liver disorders, and colorectal cancer. BiomX's lead product candidates include BX001, which addresses skin appearance issues, BX002 for inflammatory bowel disease, BX003 for bacteria related to progressive liver disease, and BX004 targeting chronic pulmonary infections caused by Pseudomonas aeruginosa. The company collaborates with notable institutions such as The Weizmann Institute of Science, Takeda, Keio University, JSR Corporation, and Janssen Research & Development to advance its microbiome-based therapeutic products. Founded in 2015, BiomX leverages innovative research from its scientific collaborators to develop novel therapeutics aimed at improving health outcomes.
Aro Biotherapeutics is focused on the development of a new protein drug platform called Centyrins, designed to achieve better efficacy and safety profiles for patients with cancer and other serious diseases. Centyrins are small, non-antibody protein scaffolds that can be expressed as multi-specifics with novel therapeutic mechanisms of action. Centyrins are also ideal for the targeted delivery of complex drug payloads, including nucleic acids.
Twentyeight-Seven, Inc. is a biotechnology company based in Watertown, Massachusetts, specializing in the development of small molecules that modulate microRNAs (miRNAs) by targeting the proteins that interact with these molecules. Their innovative approach focuses on using short non-coding RNAs to inhibit gene expression, suppress mRNA translation, and promote mRNA decay. By targeting miRNAs that play a critical role in cancer initiation, progression, and metastasis, Twentyeight-Seven aims to create effective therapeutic solutions for cancer treatment.
Magnolia Neurosciences Corporation is a New York-based company focused on drug discovery and development, specifically targeting neuroprotective therapies for central nervous system diseases and neurodegeneration. Established in 2018, the company aims to create proprietary small molecule therapeutics that prevent neuronal cell death, offering new treatment options for patients with neurodegenerative disorders and related conditions. Magnolia Neurosciences was founded to advance technologies developed at The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery Division and the Neurodegeneration Consortium. Through its innovative approach, the company seeks to address significant medical needs in the field of neurology.
V-Wave Ltd. is a medical technology company based in Caesarea, Israel, with additional offices in the United States. Founded in 2009, it specializes in the development of percutaneous implantable therapeutic devices aimed at treating chronic heart failure (HF) patients, which is a major cause of morbidity and mortality worldwide. The company has created the V-Wave Shunt, a biocompatible inter-atrial unidirectional implant designed for patients with both preserved and reduced ejection fractions, addressing the needs of those who experience disabling symptoms despite optimal medical therapy. V-Wave's innovative approach focuses on relieving symptoms, reducing hospitalizations, enhancing exercise capacity, and improving overall quality of life for HF patients. The organization is backed by a team of experienced engineers and medical scientists who have a proven track record in developing and bringing various implantable cardiovascular devices to market.
Joint Purification Systems, Inc. is a privately held company located in Solana Beach, CA. Founded in 2013, JPS is dedicated to providing novel drug and device combination products for treating musculoskeletal infection.
RefleXion Medical Inc. specializes in developing a biologically-guided radiotherapy system aimed at transforming cancer treatment. The company’s innovative technology allows tumors to continuously signal their location during therapy, facilitating the simultaneous treatment of multiple tumors, particularly in cases of metastasis. The RefleXion X1 machine is currently cleared for various forms of radiotherapy, including stereotactic body radiotherapy (SBRT) and intensity-modulated radiotherapy (IMRT). At the core of RefleXion's approach is the integration of positron-emission tomography (PET) imaging, which enables real-time tumor tracking and dose adaptation based on the biological characteristics of the tumors. This advancement in radiotherapy promises to enhance precision in cancer treatment, offering a potential paradigm shift in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic collaborations, including partnerships with Telix Pharmaceuticals and HealthMyne.
EpigenCare is a biotechnology company that specializes in personalized skincare solutions by connecting consumers with skincare brands through a digital platform. Founded in 2017 and based in Farmingdale, New York, EpigenCare offers a direct-to-consumer skincare test known as SKINTELLI, which analyzes DNA methylation levels of specific genes linked to essential skin quality factors such as aging, moisture retention, and elasticity. The platform utilizes a recommendation engine that evaluates the functional state of epigenetic markers associated with skin health, providing users with tailored suggestions for skincare products. This approach allows consumers to track the effectiveness of their skincare routines and make informed choices about the products that best suit their individual skin profiles.
Syndesi Therapeutics SA is a biopharmaceutical company based in Louvain-la-Neuve, Belgium, founded in 2018. The company focuses on developing drug molecules that modulate the synaptic vesicle protein SV2A, which is crucial for synaptic transmission—the process that facilitates communication between neurons in the brain. By regulating this transmission, Syndesi aims to create effective treatments for Alzheimer’s Disease and other cognitive impairment disorders. The company holds an exclusive license to its innovative platform technology from UCB, a leader in SV2A research. Through its efforts, Syndesi Therapeutics seeks to provide healthcare providers with advanced therapeutic options for managing these challenging conditions.
Carbon, Inc. specializes in digital manufacturing solutions, focusing on the design, development, and production of advanced 3D printing technologies. The company's proprietary Digital Light Synthesis (DLS) technology incorporates digital light projection, oxygen-permeable optics, and programmable liquid resins to create high-quality parts with superior mechanical properties and surface finishes. Carbon's offerings include the SpeedCell system for streamlined production, additive manufacturing machines based on Continuous Liquid Interface Production (CLIP) technology, and automated Smart Part Washers. These innovations support various industries, including automotive, consumer products, dental, industrial, and life sciences, by enabling mass customization and on-demand inventory, while reducing waste and production time. Additionally, Carbon provides a range of polyurethane materials and consulting services to enhance manufacturing capabilities. Founded in 2013 by Dr. Joseph DeSimone and Philip DeSimone, Carbon is headquartered in Redwood City, California.
Certa Dose, Inc. is a medical device company specializing in the design and development of color-coded syringes aimed at reducing pediatric medication dosing errors. Founded in 2013 and headquartered in Denver, Colorado, with additional operations in Indianapolis, Indiana, Certa Dose offers a patented syringe system that incorporates color confirmation to ensure accurate dosing. Its flagship product, cleared by the U.S. Food and Drug Administration, is specifically designed for administering epinephrine to pediatric patients. Each syringe features easily recognizable color zones aligned with the industry-standard Broselow pediatric color-coding system, allowing healthcare providers, including parents, nurses, doctors, and paramedics, to verify the correct dose quickly during critical situations. By matching the patient to the appropriate color zone, users can administer medication confidently, thereby enhancing patient safety and reducing the risk of medication errors in emergencies.
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.
XW Laboratories Inc. is a biopharmaceutical company based in Wuhan, China, specializing in the discovery and development of innovative treatments for neurological disorders. Established in 2014, the company has created three distinctive research and development platforms, including Prodrug and Functional Group Switch, which facilitate the rapid identification of new drug candidates while minimizing development costs and time. XW Laboratories aims to enhance patient compliance and reduce toxicity associated with existing medications. In addition to focusing on the domestic market, the company collaborates with international partners to extend its reach in foreign markets, positioning itself at the forefront of medicinal technology in the Asia-Pacific region.
Rodeo Therapeutics Corp. is a drug development company based in Seattle, Washington, focused on creating novel small molecule therapies aimed at treating inflammatory bowel disease and enhancing blood cell reconstitution after bone marrow transplants. Founded in 2017, the company specializes in targeting specific enzymes and biological pathways that are vital for tissue repair and regeneration. Its therapies work by increasing tissue levels of prostaglandin PGE2 through the inhibition of a prostaglandin-degrading enzyme, thereby facilitating tissue regeneration and protecting against conditions such as colitis. Rodeo Therapeutics is dedicated to advancing treatments that improve patient outcomes in various medical conditions related to tissue damage and recovery.
E-Scape Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapies for neurodegenerative diseases. Established in 2015 and headquartered in South San Francisco, California, the company aims to improve the lives of patients suffering from conditions such as Alzheimer’s disease, Parkinson’s disease, and sphingolipid storage disorders. E-Scape Bio is advancing a pipeline of therapeutics that target specific genetic drivers of these diseases, including ESB1609, a small molecule S1P5 receptor agonist for CNS lysosomal storage disorders, and ESB5070, a kinase inhibitor designed for Parkinson’s disease patients with the LRRK2 G2019S variant. Additionally, the company is developing a program targeting ApoE4 in Alzheimer’s disease, emphasizing its commitment to precision medicine in treating genetically defined subpopulations.
Hyalex Orthopaedics, Inc. is a medical device company based in Lexington, Massachusetts, focused on developing innovative products that utilize HYALEX technology, a synthetic polymer engineered to mimic cartilage. Founded in 2016, the company specializes in creating a biomimetic material that can effectively simulate healthy cartilage to treat diseased or damaged joints. The unique properties of HYALEX allow it to maintain low friction and wear, even under the significant loads typically experienced in human joints. This capability enables surgeons to replace arthritic cartilage while preserving healthy bone. Although Hyalex Orthopaedics is advancing its product development, its offerings have not yet received approval for use in humans from any regulatory agency.
BiomX Inc. is a clinical-stage company based in Ness Ziona, Israel, focused on developing bacteriophage-based therapies that target harmful bacteria linked to various diseases. The company aims to treat conditions associated with microbiome imbalances, including skin conditions, inflammatory bowel diseases, liver disorders, and colorectal cancer. BiomX's lead product candidates include BX001, which addresses skin appearance issues, BX002 for inflammatory bowel disease, BX003 for bacteria related to progressive liver disease, and BX004 targeting chronic pulmonary infections caused by Pseudomonas aeruginosa. The company collaborates with notable institutions such as The Weizmann Institute of Science, Takeda, Keio University, JSR Corporation, and Janssen Research & Development to advance its microbiome-based therapeutic products. Founded in 2015, BiomX leverages innovative research from its scientific collaborators to develop novel therapeutics aimed at improving health outcomes.
SuperX is a preclinical biopharmaceutical company based at the Babraham Research Campus, focused on developing novel anticoagulant therapies. The company is engaged in the discovery of antibodies targeting components of the blood coagulation cascade, aiming to create anti-thrombotic drugs that reduce the risk of bleeding. By specifically blocking thrombosis, which is a leading cause of heart attacks and strokes, SuperX seeks to provide healthcare institutions and physicians with effective anticoagulation treatments suitable for chronic use. Through its innovative approach, the company aspires to improve patient outcomes in the management of cardiovascular diseases.
Provention Bio, Inc. is a clinical-stage biopharmaceutical company based in Oldwick, New Jersey, dedicated to developing therapeutics aimed at intercepting and preventing immune-mediated diseases. The company's pipeline includes several product candidates, such as PRV-031, a monoclonal antibody currently in Phase III trials for the interception of type 1 diabetes, and PRV-6527, an oral inhibitor in Phase IIa trials for Crohn’s disease. Other notable candidates include PRV-3279, which has completed Phase 1b trials for lupus, and PRV-101, a vaccine targeting coxsackie virus B infections. Additionally, PRV-015, an anti-IL-15 monoclonal antibody, is being developed for celiac disease and is currently in Phase IIb trials. Provention Bio's innovative approach emphasizes early intervention in disease progression, positioning the company as a potential leader in a new biopharmaceutical category focused on the prevention of chronic autoimmune and inflammatory conditions.
Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, specializing in the development of diagnostic instruments and disposable cartridge systems for decentralized laboratory and point-of-care environments. The company's flagship products include the io System, which detects infectious diseases such as chlamydia and MRSA, and Callisto, designed to accommodate various testing throughput requirements. Binx Health focuses on providing solutions for sexually transmitted infections and hospital-acquired infections. The company aims to enhance healthcare accessibility by delivering on-demand testing directly to consumers, utilizing its proprietary, desktop, PCR-based platforms and mobile offerings. Established in 2005, Binx Health has formed a strategic partnership with Sherlock Biosciences to further advance its innovative healthcare solutions.
ApoGen Biotechnologies, Inc. is focused on the development of new class of therapeutics targeting drivers of cancer genomic mutation.As the arsenal of available cancer therapies has grown and evolved from cytotoxic chemotherapy to targeted therapy to immunotherapy, one fact has unfortunately remained constant nearly all cancer drug therapies eventually fail due to the development of drug resistance. Mutation of cellular DNA is central to the formation of cancer, and chronic mutation of the cancer genome is a primary cause of cancer evolution and drug resistance, resulting in ineffective therapy, cancer recurrence and metastasis, and decreased overall survival.
OrthoSpace Ltd. is a company based in Caesarea, Israel, that specializes in the development and commercialization of innovative orthopedic solutions. Founded in 2009, the company focuses on biodegradable balloon systems designed for the treatment of rotator cuff syndrome in Europe. Its flagship product, InSpace™, is a simple-to-implant device that mimics the function of the original bursa, providing a spacer between the acromion and the humeral head. This design alleviates pain and enhances the range of motion for patients suffering from rotator cuff injuries, while also facilitating smoother joint movement. InSpace™ has received the CE mark, allowing it to be marketed in Europe, and is part of OrthoSpace's commitment to creating effective orthopedic solutions that preserve bone and joint structures. As of March 2019, OrthoSpace operates as a subsidiary of Stryker Corporation.
Glyscend, Inc. is a biotechnology company focused on developing innovative therapies for metabolic diseases, particularly type 2 diabetes. Founded in 2014 and based in Baltimore, Maryland, Glyscend aims to provide a non-invasive treatment option that mimics the metabolic benefits of bariatric surgery without the need for invasive procedures. The company's core technology is an orally ingestible intestinal coating that targets the duodenum, inhibiting key neurohormonal pathways to help regulate glucose levels effectively. This approach not only seeks to improve patient outcomes by addressing diabetes directly but also aims to minimize common side effects associated with traditional treatments, such as weight gain and hypoglycemia. Glyscend is committed to equipping healthcare providers with effective tools for treating diabetes, moving beyond mere management of the disease.
BlackThorn Therapeutics operator of a clinical-stage biopharmaceutical company intended to develop precision medicine for disorders of the central nervous system (CNS) based on advances in computational and clinical neuroscience. The company leverages a deep understanding of brain and behavior relationships that seeks to overcome historic challenges in drug discovery and development by targeting dysfunctional brain circuits. Its proprietary computational platform, the company seeks to identify novel targets, small molecule drug candidates and biologically-based patient subgroups most likely to respond to treatment.
TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, dedicated to developing and commercializing targeted therapeutics for cancer and wet age-related macular degeneration (AMD). The company's lead product is envafolimab, an investigational PD-L1 single-domain antibody aimed at treating soft tissue sarcoma. Other notable candidates include DE-122, which is undergoing a randomized Phase IIa study for wet AMD; TRC102, a small molecule currently in multiple clinical trials for various cancers, including mesothelioma and lung cancer; TRC253, in Phase II trials for metastatic castration-resistant prostate cancer; and TJ004309, a CD73 antibody in Phase I development for solid tumors. TRACON has established collaborations and licensing agreements with several organizations, including 3D Medicines and Janssen Pharmaceutica, to advance its product development. TRACON was originally founded in 2004 and underwent a name change from Lexington Pharmaceuticals in 2005.
Torax Medical, Inc. develops and markets products/devices to restore the barrier function of sphincters. The company’s products include LINX, a reflux management system to treat patients diagnosed with gastroesophageal reflux disease; and FENIX, a continence restoration system for the treatment of fecal incontinence. It sells its products in Europe and the United States. Torax Medical, Inc. was founded in 2002 and is based in Shoreview, Minnesota. As of March 23, 2017, Torax Medical, Inc. operates as a subsidiary of Ethicon, Inc.
RefleXion Medical Inc. specializes in developing a biologically-guided radiotherapy system aimed at transforming cancer treatment. The company’s innovative technology allows tumors to continuously signal their location during therapy, facilitating the simultaneous treatment of multiple tumors, particularly in cases of metastasis. The RefleXion X1 machine is currently cleared for various forms of radiotherapy, including stereotactic body radiotherapy (SBRT) and intensity-modulated radiotherapy (IMRT). At the core of RefleXion's approach is the integration of positron-emission tomography (PET) imaging, which enables real-time tumor tracking and dose adaptation based on the biological characteristics of the tumors. This advancement in radiotherapy promises to enhance precision in cancer treatment, offering a potential paradigm shift in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic collaborations, including partnerships with Telix Pharmaceuticals and HealthMyne.
WellDoc, Inc. is a digital health company focused on chronic disease management, particularly diabetes care. Founded in 2005 and headquartered in Baltimore, Maryland, WellDoc offers innovative solutions such as the DiabetesManager platform and BlueStar mobile prescription therapy. The DiabetesManager platform facilitates patient-provider coordination through features like personalized coaching, medication reminders, and real-time alerts, while BlueStar offers patients immediate guidance to enhance self-management of diabetes. WellDoc’s services also include clinical decision support for healthcare professionals and a comprehensive suite of technical services, such as software development and regulatory management. The company aims to improve health outcomes and reduce healthcare costs by integrating behavioral and motivational applications with everyday technology. WellDoc serves a diverse range of clients, including payors, employers, pharmaceutical and medical device companies, and healthcare providers.
Inivata Limited is a clinical cancer genomics company based in Cambridge, United Kingdom, established in 2014. The company specializes in the analysis of circulating tumor DNA (ctDNA) to enhance cancer testing and treatment for oncologists and their patients. By utilizing its TAm-Seq technology, Inivata enables the detection and analysis of genomic material from a patient's cell-free ctDNA, collected through a simple blood sample. This non-invasive method, known as liquid biopsy, represents a significant advancement in cancer diagnostics, allowing for improved detection, monitoring, and treatment decision-making. Inivata has also formed a strategic collaboration with NeoGenomics, Inc. to further strengthen its capabilities in this field.
V-Wave Ltd. is a medical technology company based in Caesarea, Israel, with additional offices in the United States. Founded in 2009, it specializes in the development of percutaneous implantable therapeutic devices aimed at treating chronic heart failure (HF) patients, which is a major cause of morbidity and mortality worldwide. The company has created the V-Wave Shunt, a biocompatible inter-atrial unidirectional implant designed for patients with both preserved and reduced ejection fractions, addressing the needs of those who experience disabling symptoms despite optimal medical therapy. V-Wave's innovative approach focuses on relieving symptoms, reducing hospitalizations, enhancing exercise capacity, and improving overall quality of life for HF patients. The organization is backed by a team of experienced engineers and medical scientists who have a proven track record in developing and bringing various implantable cardiovascular devices to market.
Aelix Therapeutics SL is a biotechnology company based in Barcelona, Spain, focused on developing therapeutic vaccines and immunotherapies for the treatment of HIV infection. Established in 2015, Aelix Therapeutics emerged as a spin-off from HIVACAT, a Catalan initiative aimed at creating effective HIV vaccines. The company is led by a team of experienced professionals in the fields of HIV and biotechnology, including Dr. Christian Brander, Bonaventura Clotet, Josep Maria Gatell, and Jordi Naval. Aelix Therapeutics leverages innovative immunogen designs to enhance its therapeutic approaches and has established partnerships that provide access to extensive cohorts of HIV-infected patients across various continents, facilitating clinical research and development. The company's vaccine strategy is based on a T-cell immunogen that has the potential to elicit strong immune responses, aiming to transform the treatment landscape for HIV and improve patient outcomes.
Lodo Therapeutics Corporation is a drug discovery and development company dedicated to creating novel therapeutics derived from natural sources to address significant health challenges, particularly resistant infectious diseases and cancers. Founded to advance the scientific vision of Dr. Sean Brady from Rockefeller University, Lodo utilizes a genome-based, culture-independent platform to discover and characterize small molecules from microbial sources found in soil. By leveraging advancements in DNA sequencing and bioinformatics, the company aims to unlock the therapeutic potential of previously undiscovered molecules encoded in microbial DNA, with a focus on treating conditions that have high unmet medical needs. Lodo Therapeutics, supported by Accelerator Corporation, is headquartered in New York City, where its laboratory and offices are located within the Alexandria Center for Life Science.
Petra Pharma Corporation is a clinical-stage pharmaceutical company based in New York that focuses on discovering and developing therapies for serious medical conditions, particularly cancer and metabolic diseases. Incorporated in 2015, the company specializes in modulating phosphoinositide (PI) signaling pathways and targets novel enzyme mechanisms that are vital for critical cellular processes such as cell division, growth, trafficking, and signaling. By developing small molecules that interact with these pathways, Petra Pharma aims to create innovative treatment options that can significantly improve patient health outcomes.
Navitor Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing small molecule drugs that target mTORC1, a key regulator of cellular metabolism and renewal, to treat age-related diseases. Utilizing a proprietary platform, Navitor's therapies can selectively inhibit or activate mTORC1, which plays a crucial role in cellular processes. One of its notable products, NV-5138, is an orally bioavailable small molecule designed to activate mTORC1, particularly addressing its suppression in the brain associated with depression. Additionally, the company's N-Valog program focuses on selective inhibition of mTORC1 for chronic kidney disease, with implications for other age-related conditions. Founded in 2009 and headquartered in Cambridge, Massachusetts, Navitor Pharmaceuticals aims to unlock the therapeutic potential of the mTOR pathway by modulating nutrient-sensing proteins, thereby addressing various metabolic, neurodegenerative, autoimmune, and musculoskeletal diseases.
First Aid Shot Therapy is a company specializing in clinical beverages aimed at addressing acute and chronic health needs. Founded in 2010 and headquartered in Burlingame, California, it offers a variety of easy-to-swallow, single-dose products that deliver fast-acting relief for common everyday symptoms such as hangovers, pain, sleep issues, colds, allergies, and heartburn. The company's focus is on providing effective solutions that help consumers manage their symptoms quickly and conveniently.
Asceneuron SA is a biotechnology company based in Lausanne, Switzerland, founded in 2012, that focuses on discovering and developing therapeutics for neurodegenerative disorders with significant unmet medical needs. The company targets conditions such as progressive supranuclear palsy, orphan tauopathies, Alzheimer’s disease, and Parkinson’s disease. Asceneuron aims to develop orally bioavailable small molecule drugs that address both symptomatic relief and disease progression for these debilitating conditions. Tauopathies, characterized by the accumulation of tau protein deposits in the brain, are a key area of focus, as they currently lack effective treatments. With the increasing prevalence of Alzheimer's disease posing a major healthcare challenge, Asceneuron aspires to become a leading entity in the biotech sector by providing innovative and more effective therapeutic options for patients suffering from neurodegenerative diseases. The company operates as a subsidiary of Merck KGaA.
Merus N.V. is a clinical-stage immuno-oncology company based in the Netherlands, focused on the discovery and development of bispecific antibody therapeutics. The company's pipeline includes several promising candidates, notably MCLA-128, currently in phase 2 clinical trials for metastatic breast cancer; MCLA-117, in phase I trials for acute myeloid leukemia; and MCLA-158, also in phase I trials for solid tumors. Additionally, Merus is advancing other bispecific antibody candidates, including MCLA-129 and MCLA-145, in collaboration with various pharmaceutical partners. The company employs a unique technology called Oligoclonics, which enables the production of a mixture of therapeutic antibodies from a single cell clone, aimed at targeting common antigens. Merus has established partnerships to enhance its research capabilities, such as its collaboration with Caris Life Sciences for detecting NRG1 fusions in cancer patients. Founded in 2003, Merus is headquartered in Utrecht and is dedicated to developing innovative treatments for cancer.
Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat central nervous system (CNS) diseases. Our goal is to transform the lives of patients with improved therapeutic options and a patient-centric focus. Leveraging extensive domain expertise, we have identified and acquired or in-licensed a portfolio of development-stage proprietary compounds with innovative mechanisms of action.
DJS Antibodies Ltd, founded in 2014 and based in Bicester, United Kingdom, specializes in the design and discovery of innovative therapeutic monoclonal antibodies targeting G-protein-coupled receptors (GPCRs). The company is focused on addressing significant unmet medical needs through the development of new medicines, an inherently challenging process often hindered by traditional methodologies. DJS Antibodies utilizes a breakthrough technology that enhances the success rate of discovering lead antibodies, a process that has garnered early support from Johnson & Johnson. This approach has facilitated the advancement of lead programs aimed at treating cancer and kidney disease, positioning DJS Antibodies as a leader in the field of drug development.
Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, specializing in the development of diagnostic instruments and disposable cartridge systems for decentralized laboratory and point-of-care environments. The company's flagship products include the io System, which detects infectious diseases such as chlamydia and MRSA, and Callisto, designed to accommodate various testing throughput requirements. Binx Health focuses on providing solutions for sexually transmitted infections and hospital-acquired infections. The company aims to enhance healthcare accessibility by delivering on-demand testing directly to consumers, utilizing its proprietary, desktop, PCR-based platforms and mobile offerings. Established in 2005, Binx Health has formed a strategic partnership with Sherlock Biosciences to further advance its innovative healthcare solutions.
XW Laboratories Inc. is a biopharmaceutical company based in Wuhan, China, specializing in the discovery and development of innovative treatments for neurological disorders. Established in 2014, the company has created three distinctive research and development platforms, including Prodrug and Functional Group Switch, which facilitate the rapid identification of new drug candidates while minimizing development costs and time. XW Laboratories aims to enhance patient compliance and reduce toxicity associated with existing medications. In addition to focusing on the domestic market, the company collaborates with international partners to extend its reach in foreign markets, positioning itself at the forefront of medicinal technology in the Asia-Pacific region.
ViaCyte, Inc. is a regenerative medicine company based in San Diego, California, focused on developing innovative cell replacement therapies for diabetes. The company is working on several product candidates, including VC-01, designed for type 1 diabetes, and VC-02, which facilitates blood vessel interaction with implanted pancreatic precursor cells. Their VCTX210 product utilizes a proprietary human stem cell line that helps prevent immune system rejection, eliminating the need for immunosuppressants. ViaCyte's therapies differentiate stem cells into pancreatic beta-cell precursors that are implanted in an encapsulation device, enabling the production of insulin in response to blood glucose levels. The company's aim is to provide long-term solutions for both type 1 and type 2 diabetes patients, reducing their dependence on insulin and minimizing associated health complications. Founded in 1999 and formerly known as Novocell, Inc., ViaCyte also has operations in Athens, Georgia.
Cartiheal Ltd., a medical device company, develops implants for the regeneration of cartilage and bone disorders. The company offers Agili-C, an off the shelf and cell-free implant that regenerates hyaline cartilage and its underlying subchondral bone. Its implant is used for the treatment of focal articular cartilage and osteochondral defects. The company was founded in 2009 and is based in Kfar Sava, Israel.
Cartiheal Ltd., a medical device company, develops implants for the regeneration of cartilage and bone disorders. The company offers Agili-C, an off the shelf and cell-free implant that regenerates hyaline cartilage and its underlying subchondral bone. Its implant is used for the treatment of focal articular cartilage and osteochondral defects. The company was founded in 2009 and is based in Kfar Sava, Israel.